Market Trends Influencing Strategic Decisions in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry: Innovative Oral Treatments Drive Growth In The Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, and What Factors Will Drive It?
The market for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment has witnessed exponential growth in recent times. It is projected to inflate from $10.36 billion in 2024 to $13.29 billion by the year 2025, signifying a Compound Annual Growth Rate (CAGR) of 28.2%. Factors such as the upward trend in occurrences of Transthyretin Amyloid Cardiomyopathy, heightened cases of Transthyretin Amyloidosis in the elderly population, increased awareness amongst healthcare practitioners and patients, and enhancements in healthcare services have all catalyzed this growth during the historic period.
The market size for the treatment of transthyretin amyloid cardiomyopathy (attr-cm) is predicted to significantly increase in the forthcoming years. It’s projected to reach$35.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 27.8%. The growth during this predicted period can be credited to a rise in transthyretin amyloidosis cases, an increase in neuropathic disorder diagnoses, an ageing demographic, higher demand for specific drugs to manage the symptoms of this rare disease, and an overall increase in healthcare demand. Key trends for the forecast period comprise novel diagnostic technologies, breakthrough techniques for therapy management, innovative and targeted treatments for transthyretin amyloidosis, and advancements in diagnostic and cardiac MRI techniques.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The escalating incidence of chronic illnesses is anticipated to stimulate the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, which are long-term ailments that evolve gradually and last for more than a year, often necessitating ongoing medical attention. This upsurge in chronic conditions can be linked to factors like increasing age, sedentary ways of life, unhealthy eating habits, a rise in obesity, and contact with environmental toxins. The treatment for transthyretin amyloid cardiomyopathy works by stabilizing transthyretin, reducing the accumulation of amyloid, enhancing heart performance, and mitigating symptoms for optimal handling of associated chronic disorders. For example, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in September 2023, that there were 41 million deaths, representing 74% of deaths caused by non-communicable diseases (NCDs) or chronic ailments each year. Worldwide, cardiovascular diseases contributed to 17.9 million deaths, cancer to 9.3 million deaths, chronic respiratory diseases to 4.1 million deaths, and diabetes to 2.0 million deaths. Consequently, the prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Which Key Market Segments Comprise the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market and Drive Its Revenue Growth?
The transthyretin amyloid cardiomyopathy (attr-cm) treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
3) By RNAi Therapy: Patisiran; Vutrisiran
4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Which Areas Are Leading Regions in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Expansion Across the Globe?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theTransthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Direction?
Major firms in the ATTR-CM treatment market are putting their efforts into the development of groundbreaking therapies for ATTR-CM, like oral medication that aims to stabilize TTR proteins or minimize the accumulation of amyloid fibril in the heart. Oral prescription medication, usually distributed in the form of tablets, capsules, or liquid solutions, is a category of drugs recommended by trained healthcare professionals for consumption orally. For example, the U.S. Food and Drug Administration granted approval to the US biotech firm, BridgeBio Pharma Inc., in November 2024 for its drug, Attruby (acoramidis), designed for treating adults with ATTR-CM. It imparts stability to the TTR protein, thereby decreasing the rate of hospitalizations and fatalities linked to heart conditions. Clinical studies suggest that the drug is well-tolerated and offers quick benefits by addressing the underlying cause of the illness.
View the full report here:
How Is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Conceptually Defined?
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
